FDCNSEFDC Limited· PharmaceuticalsLowNeutral
Announced Wed, 16 Jul · 18:27 IST

The Exchange had sought clarification from FDC Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed.

Regulatory & Legal View source PDF

FDC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

FDC told the NSE that the 'Total Equity & Liabilities' line was inadvertently left out during the scanning of its Q4 and FY25 results, but the underlying data and XBRL filing were complete and correct. The company resubmitted the correctly scanned copy, and the exchange query is now closed. Along with the clarification, the full audited results were furnished: consolidated revenue from operations for FY25 rose to Rs 2,10,812 lakhs from Rs 1,94,294 lakhs in FY24, while consolidated profit after tax fell to Rs 26,679 lakhs from Rs 30,506 lakhs. Standalone FY25 net profit stood at Rs 27,363 lakhs, EPS was Rs 16.81 (standalone, annualised), and total assets reached Rs 2,71,380 lakhs. The statutory auditor gave an unmodified opinion, and an interim dividend of Rs 5 per share was paid for FY25.

Likely market impact

This is a procedural, paper-based issue with no change in actual financials, so no material impact on shareholders or the stock is expected. The YoY decline in FY25 consolidated profit is worth tracking, though it was partly influenced by fair-value gains/losses on financial instruments.